
    
      BIM deletion polymorphism was a poor clinical response marker to EGFR-TKIs in NSCLC patients
      who had EGFR mutations. In the study, the investigators want to use EGFR-TKI with
      chemotherapy as 1 st treatment in stage IIIB/IV NSCLC patients with both EGFR mutation and
      BIM deletion polymorphism.
    
  